Vaxcyte appointed David McAvoy as Chief Legal Officer and Luis Jodar as Chief Medical Officer on August 31, 2026. The company narrowed its guidance for topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial, now expecting results by the end of October 2026 instead of the previously communicated fourth quarter. Vaxcyte is a clinical-stage vaccine innovation company developing high-fidelity vaccines for bacterial diseases.
